The global catheter-associated urinary tract infections (CAUTI) treatment market is anticipated to witness steady growth, with a projected compound annual growth rate (CAGR) of 3.0%. According to recent projections, the market value is expected to increase from USD 1.31 billion in 2023 to USD 1.76 billion by 2033. Following a valuation of USD 1.26 billion at the end of 2022, the market is expected to exhibit year-over-year growth of 3.9% in 2023.
Key Growth Drivers
Several factors are contributing to the growth of the CAUTI treatment market:
- Rising Incidence of Urinary Tract Infections: The increasing prevalence of urinary tract infections, particularly in catheterized patients, is driving demand for effective treatment options and management strategies.
- Advancements in Treatment Approaches: Ongoing research and innovation in treatment modalities are leading to the development of new antibiotics and alternative therapies aimed at managing CAUTIs more effectively.
- Focus on Infection Control Measures: Healthcare facilities are increasingly prioritizing infection prevention and control measures, which can enhance the demand for effective CAUTI treatments.
As assessed by Future Market Insights, among the drug type, quinolones held a market share of around 37.6% in the global market, in 2022. In 2022, the catheter associated urinary tract infections treatment market sales accounted for a revenue share of 72.3% in the global complicated UTI market, which was valued at around US$ 1.8 Billion.
Competition Landscape
The treatment market for catheter-associated urinary tract infections treatment is competitive. In addition to expanding their presence in emerging markets through new partnerships and merger acquisitions, market leaders are concentrating on the introduction of technologically advanced products. The competitive environment includes an analysis of a handful of global and local corporations that control the majority of the market share. In addition to acquisitions, mergers, and partnerships with key market participants.
Some key instances of development include:
- In June 2019, it was announced by Merck that a definitive agreement has been entered into with Tilos Therapeutics for the development of drugs to treat cancer, fibrosis, and autoimmune diseases.
- In November 2018, Allergan announced that the FDA has accepted the Supplemental New Drug Application for Avycaz to treat patients with Complicated Urinary Tract Infections (CUTI) and Complicated Intra-Abdominal Infections (CIAI).
Key Companies Covered
- Pfizer Inc.
- Merck & Co., Inc.
- GlaxoSmithKline (GSK)
- AstraZeneca
- Bayer AG
- Johnson & Johnson
- Novartis International AG
- Sanofi
- Roche Holding AG
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Abbott Laboratories
- Astellas Pharma Inc.
- Boehringer Ingelheim
- Daiichi Sankyo Company, Limited
- Gilead Sciences, Inc.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Lupin Limited
Grab Your Complete Report Instantly
Key Segments Covered in Urinary Tract Infections Treatment Industry Research
Drug Type:
- Penicillin & Combinations
- Amoxicillin
- Amoxicillin+ Clavulanate Potassium
- Others
- Quinolones
- Ciprofloxacin
- Levofloxacin
- Nalidixic acid
- Norfloxacin
- Others
- Cephalosporin
- Ceftriaxone
- Cefuroxime
- Cefixime
- Cephalexin
- Aminoglycoside Antibiotics
- Amikacin
- Gentamicin
- Sulphonamides (Sulfamethoxazole +Trimethoprim)
- Azoles and Amphotericin B
- Tetracycline (Doxycycline)
- Nitrofurans (Nitrofurantoin)
- Other
Indication Type:
- Asymptomatic CAUTI (Bacteriuria)
- Symptomatic CAUTI (Bacteremic)
Distribution Channel:
- Hospital Pharmacies
- Gynaecology and Urology Clinics
- Drug Stores
- Retail Pharmacies
- Online Drug Stores
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
